Department of Cardiology, Amsterdam UMC, Heart Centre, Amsterdam Cardiovascular Sciences, the Netherlands (R.G.T.F., C.K.M.B., J.W., C.E.M.V., G.A.d.W., Y.A., K.M.J.M., R.J.d.W., M.A.M.B., T.P.v.d.H., J.J.P.).
HeartLife klinieken, Utrecht, the Netherlands (M.E.W.).
Circ Cardiovasc Interv. 2022 Aug;15(8):e012017. doi: 10.1161/CIRCINTERVENTIONS.122.012017. Epub 2022 Jul 29.
Coronary function testing in patients with ischemia and nonobstructive coronary arteries (INOCA) commonly includes assessment of adenosine-mediated vasodilation and acetylcholine spasm provocation. The purpose of this study was to evaluate the diagnostic value of additional endothelial function testing for the diagnosis of vasomotor dysfunction in patients with INOCA.
In this retrospective cohort study, we included patients with INOCA who underwent clinically indicated comprehensive coronary function testing. Endothelial dysfunction was defined as a <50% increase in coronary blood flow, determined by Doppler flow, and/or epicardial vasoconstriction compared to baseline, in response to low-dose acetylcholine. Coronary artery spasm (CAS) was defined as vasospastic angina or microvascular angina in response to coronary high-dose acetylcholine. An impaired adenosine-mediated vasodilation was defined as a coronary flow reserve <2.5 and/or hyperemic microvascular resistance ≥2.5.
Among all 110 patients, 79% had endothelial dysfunction, 62% had CAS, and 29% had an impaired adenosine-mediated vasodilation. Endothelial dysfunction was present in 80% of patients who tested positively for CAS and/or an impaired adenosine-mediated vasodilation. Endothelial function testing increases the diagnostic yield of coronary function testing that only incorporates adenosine testing and spasm provocation by 17% to 92%. Of patients with normal adenosine-mediated vasodilation and no inducible CAS, 68% had endothelial dysfunction.
Concomitant endothelial dysfunction was prevalent in the vast majority of patients with INOCA with inducible CAS and/or an impaired adenosine-mediated vasodilation. In patients with INOCA without inducible CAS and normal adenosine-mediated vasodilation, two-thirds had endothelial dysfunction. These results indicate the relevance to perform endothelial function testing in patients with INOCA in view of its therapeutic implication.
在有缺血但非阻塞性冠状动脉(INOCA)的患者中,冠状动脉功能检测通常包括腺苷介导的血管舒张和乙酰胆碱痉挛激发的评估。本研究的目的是评估额外的内皮功能检测对诊断 INOCA 患者血管运动功能障碍的诊断价值。
在这项回顾性队列研究中,我们纳入了接受临床指征明确的全面冠状动脉功能检测的 INOCA 患者。内皮功能障碍定义为与基线相比,低剂量乙酰胆碱反应时,通过多普勒血流和/或心外膜血管收缩,冠状动脉血流减少<50%。冠状动脉痉挛(CAS)定义为对冠状动脉高剂量乙酰胆碱反应时出现痉挛性心绞痛或微血管性心绞痛。腺苷介导的血管舒张受损定义为冠状动脉血流储备<2.5 和/或充血性微血管阻力≥2.5。
在所有 110 例患者中,79%有内皮功能障碍,62%有 CAS,29%有腺苷介导的血管舒张受损。在检测出 CAS 和/或腺苷介导的血管舒张受损阳性的患者中,80%存在内皮功能障碍。内皮功能检测将仅包含腺苷检测和痉挛激发的冠状动脉功能检测的诊断率提高了 17%至 92%。在腺苷介导的血管舒张正常且无诱导性 CAS 的患者中,68%有内皮功能障碍。
在有诱导性 CAS 和/或腺苷介导的血管舒张受损的大多数 INOCA 患者中,同时存在内皮功能障碍。在无诱导性 CAS 和腺苷介导的血管舒张正常的 INOCA 患者中,三分之二有内皮功能障碍。这些结果表明,鉴于内皮功能障碍具有治疗意义,在 INOCA 患者中进行内皮功能检测是相关的。